Bai Xianhong, Chairman of Biotech Pharmaceuticals Co Ltd

Bai Xianhong, Chairman of Biotech Pharmaceuticals Co Ltd

Bai obtained his master's degree in environmental science and engineering at Tsinghua University.

He was a visiting scholar to the University of California in the United States and has years of management experience in science and technology

In August 2008, he established Biotech Pharmaceuticals Co Ltd, a high-tech biomedical enterprise created as a Sino-Cuba joint venture. The company specializes in the research and manufacture of monoclonal antibody drugs and tumor therapeutic vaccines which treat malignant tumors.

Biotech broke technical barriers in China's biomedical industry through a decade of exploration. It established the largest and most advanced humanized monoclonal antibody research, development and industrialization base in China.

Biotech's product Nimotuzomab is the only humanized monoclonal antibody drug developed in China.